Allergan Inc. (AGN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Allergan ( AGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.5%. By the end of trading, Allergan rose 99 cents (1.1%) to $89.84 on average volume. Throughout the day, two million shares of Allergan exchanged hands as compared to its average daily volume of two million shares. The stock ranged in a price between $88.98-$90.51 after having opened the day at $89.16 as compared to the previous trading day's close of $88.85. Other companies within the Drugs industry that increased today were: OxiGene ( OXGN), up 30.2%, Catalyst Pharmaceutical Partners ( CPRX), up 28.4%, Cormedix ( CRMD), up 26.3%, and DARA Biosciences ( DARA), up 20.9%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $26.83 billion and is part of the health care sector. The company has a P/E ratio of 26.1, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 1.6% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Allergan a buy, one analyst rates it a sell, and eight rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, RBS Oil Trendpilot Exchange Traded Notes ( TWTI), down 9.9%, Columbia Laboratories ( CBRX), down 8.9%, Optimer Pharmaceuticals ( OPTR), down 6.6%, and Aoxing Pharmaceutical Company ( AXN), down 6.3%, were all laggards within the drugs industry with Shire ( SHPG) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

null

More from Markets

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet